Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00714259 · ClinicalTrials.gov registry record · Phase 2
Non-Myeloablative Allogeneic HSCT From HLA Matched Related or Unrelated Donors for the Treatment of Low Grade B Cell Malignancies
A Phase 2 study, sponsored by University of Alabama at Birmingham.
- Terminated
- Registry status
- Phase 2
- Development phase
- 5
- Enrollment target
NCT00714259 is a Phase 2 study that was terminated before completion, run by University of Alabama at Birmingham. The registered enrollment target is 5 participants.
The verdict
NCT00714259, a Phase 2 study, was terminated before completion, sponsored by University of Alabama at Birmingham.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 5 participants
- Enrollment target
Study Summary
A non-myeloablative treatment strategy and uniform selection criteria will enable patients with a variety of low grade B-Cell malignancies to attain long term disease control without unacceptably high treatment related mortality.
Interventions
- DRUG Fludarabine
- RADIATION Total Body Irradiation
- OTHER Infusion of Stem Cells
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2008-07 |
| Est. Completion | 2013-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00714259
The ClinicalTrials.gov registry entry for NCT00714259 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Alabama at Birmingham, which has 1,160 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Fludarabine is the first listed.
NCT00714259 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00714259 about?
NCT00714259 is a clinical study titled "Non-Myeloablative Allogeneic HSCT From HLA Matched Related or Unrelated Donors for the Treatment of Low Grade B Cell Malignancies". A non-myeloablative treatment strategy and uniform selection criteria will enable patients with a variety of low grade B-Cell malignancies to attain long term disease control without unacceptably high treatment related mortality.
What is the current status of trial NCT00714259?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 5 participants. The study started on 2008-07. Estimated completion is 2013-02.
What interventions are being tested in trial NCT00714259?
The interventions under investigation include: Fludarabine (DRUG), Total Body Irradiation (RADIATION), Infusion of Stem Cells (OTHER).
Who is sponsoring clinical trial NCT00714259?
This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.